An update on familial pancreatic cancer and the management of asymptomatic relatives  by Windsor, John A.
REVIEW ARTICLE
An update on familial pancreatic cancer and the management of
asymptomatic relatives
JOHN A. WINDSOR
Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
Abstract
Families of patients with pancreatic adenocarcinoma (PC) often ask about their own risk of developing this disease. There is
now a sufficient body of evidence to inform relatives of their relative risk of developing PC. The purpose of this review is to
provide practical advice for the clinician when confronted with questions about the risk of PC in relatives, and the role of
genetic testing and screening in high-risk individuals.
Introduction
The importance of this topic is underscored by the
dismal prognosis of pancreatic adenocarcinoma (PC),
with an overall 5-year survival of B/5% [1,2]. The best
chance of reducing the high mortality of PC is the
identification of individuals at risk and the develop-
ment of screening tests for early diagnosis and
treatment [3]. The proof that early detection prolongs
life is still wanting.
The majority of PC cases are sporadic, with no
known inherited predisposition. It has been com-
monly stated that familial PC (FPC) is responsible for
10% of cases of PC [4]. More recent prospective
studies from Sweden and Germany, using strict
criteria of confirmation by histology and medical
records, suggest that the familial proportion of PC is
only 1.92.7% [5,6]. Nevertheless, family history of
PC remains an important risk factor for developing
PC.
Familial pancreatic cancer is one of several
clinical settings in which an inherited predisposition
to PC can be found. These include hereditary
pancreatitis, cystic fibrosis and defined familial
cancer syndromes [7] (Table I), for which the
gene mutations and lifetime risk of cancers have
been estimated [8]. Aside from these syndromes,
which account for the minority of FPC cases, the
major gene(s) responsible for the inheritance pat-
terns of PC remains to be identified. The inheri-
tance pattern is probably autosomal dominant with
variable penetrance [7].
Definition of familial pancreatic cancer
There is no agreed definition of FPC, although the
one most widely accepted is kindreds with two or
more family members who have been diagnosed with
pancreatic cancer and who are first degree relatives [8]
and who are not part of a familial cancer syndrome.
The familial aggregation of PC is not just due to
hereditary predisposition, but is also influenced by
variable gene penetrance (not all gene carriers will
develop PC), environmental factors, family size and
chance.
Presentation of familial pancreatic cancer
Although an early age of onset of PC would be
expected in these families, it has not been proven
[9,10]. The manner of presentation is similar to those
with sporadic PC. Even in the context of a national
registry where there were 25 incipient cases of PC, 22
presented with metastatic disease at the time of
presentation [11]. This is remarkable because the
individuals were aware of the signs and symptoms of
PC through their experiences with family members
who died of pancreatic cancer. Thus FPC, like
sporadic cancer, is usually diagnosed with sympto-
matic and advanced disease.
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Risk of pancreatic cancer in first degree relatives
First-degree relatives of patients with FPC form a
high-risk group of individuals. Two recent publica-
tions have helped to quantify the relative risk of
developing PC in first degree relatives.
The first major prospective study of incipient PC
occurring in FPC kindreds comes from the John
Hopkins Medical Institutions, Baltimore, using the
National Familial Pancreas Tumor Registry [9]. They
estimated risk by comparing observed new cases of
PC during the observation period with expected
numbers based on the United States population-
based Surveillance, Epidemiology and End Results
(SEER) program data. They found that the risk of PC
among 191 sporadic kindreds was not significantly
greater than expected, with an incidence rate of 24.5
cases per 100 000 per year. Overall there was an 18-
fold risk of PC among first degree relatives in FPC
kindreds, which equates with an incidence of 76 cases
per 100 000 per year. In the subset of FPC kindreds
with 3 or more affected first degree relatives there was
a 57-fold increased risk of PC with an incidence of
310 cases per 100 000 per year.
The second publication is an extension of this
study, and involved quadrupling the follow-up [11].
There were 5179 individuals from 838 kindreds (370
FPC kindreds) followed for 14 128 personal years.
The standardized incidence rates (as above) of PC
were 4.5 (confidence interval (CI) 0.5416.3) for one
first degree relative with PC, 6.4 (CI, 1.816.4) for
two first degree relatives and 32 (CI, 10.4-74.7) for
three or more first degree relatives. This translates to
an estimated incidence of pancreatic cancer of 41, 58
and 288 per 100 000, respectively, compared with the
reference of 9 per 100 000 in the general US popula-
tion.
Cigarette smoking and the risk of PC
A number of environmental factors are thought to
further increase the risk of PC in individuals from
FPC kindred. Cigarette smoking is an independent,
significant risk factor; it is the most important
identified risk factor and is more so in men and
younger FPC members [10]. Other risk factors are
reviewed elsewhere [8]. An interaction between family
history and smoking was first reported in 2001 [9,12].
More recent work has determined that smoking
increases the risk of PC in FPC kindred fourfold,
and that it hastens the onset of the disease by 10 years
[10]. This is important because it influences the
timing of screening. Smoking cessation reverses this
risk, but takes at least a decade to do so.
Identification of high-risk individuals
The key step in estimating the risk of PC in an
individual is the analysis of the family tree over at least
three generations. If the individual (or proband)
appears to be at increased risk, then it is appropriate
to involve a clinical genetics service. A formal pedigree
analysis will be undertaken, allowing a more accurate
estimation of risk. In addition the individual should
have access to genetic counselling that should include
a discussion about the role of genetic testing, registries
and screening.
Genetics of FPC and role of gene testing
Familial pancreatic cancer may be a genetically
heterogeneous disorder caused by mutations in dif-
ferent oncogenes and/or modifier genes, but recent
segregation studies suggest that FPC may be caused
by a single major gene [13]. Although an FPC gene
has not been identified, a PC susceptibility locus has
been mapped to chromosome 4q32-34 in a large
kindred with an autosomal dominant inheritance
pattern [14]. This is a unique locus, not associated
with the recognized familial cancer syndromes. Ad-
vances like this offer hope that gene testing will have a
clinical role in the future.
There are a number of benefits of gene testing
including defining personal cancer aetiology, deter-
mining the risk to siblings and offspring, and aiding
decision making around screening, surveillance and
treatment. However, the real value of gene testing is
only when treatment is based on genetic information.
There are also potentially important clinical, psycho-
logical and social consequences to gene testing that
should only be considered after genetic counselling.
While gene testing is possible it is not always advisable
Table I. Clinical syndromes and diseases with defined gene alterations, the chromosome locus and cumulative lifetime risk of developing
pancreatic adencarcinoma.
Syndrome/disease Gene(s) Locus Lifetime risk
Hereditary breast/ovarian cancer BRCA2 13q 5%
FAMM melanoma syndrome CDKN2A 9p 19%
Cystic fibrosis CFTR 7q 25%
Peutz-Jeghers syndrome STK11 19p 35%
Hereditary pancreatitis PRSS1, SPINK 1 7q, 5q 40%
Familial adenomatous polyposis APC 5q ?
Hereditary non-polyposis colon cancer DNA MMR 2p, 3p ?
FAMM, familial atypical multiple mole; MMR, mismatch repair.
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and there remain a number of key questions about
how well gene testing actually measures what it
purports to measure (analytical validity) and the
clinical validity (how well it predicts PC) and utility
(likelihood that a positive result lead to improved
outcome) of individual tests.
There are a number of known oncogenes and
tumour suppressor genes that are either activated or
inactivated in the progression from precursor lesions
to PC [15]. The current understanding of the genetics
of pancreatic cancer has been reviewed recently
[2,16]. The role of gene testing in individuals thought
to have one of the recognized familial cancer syn-
dromes (Table I) is well established. The situation is
much less clear for individuals from FPC kindreds.
The current position is that gene testing outside of
controlled studies should be avoided because we do
not know the relevant germline mutations in FPC [3].
Consideration should be given to the storage of serum
for subsequent gene testing when more is known
about the genetics of FPC.
Registration
The registration of individuals at high risk is impor-
tant. The collection of FPC kindreds offers an
important opportunity to evaluate pathogenesis, nat-
ural history, biomarkers, underlying gene alterations,
new diagnosis, treatment and chemoprevention stra-
tegies. In addition, knowledge gained from the study
of FPC might be useful in improving the diagnosis,
management and prognosis of sporadic PC. There are
a number of established registries around the world,
and advice can be sought for the registry most
appropriate for the individual concerned.
Screening and surveillance
Although there are no established standards for
defining a high-risk population for screening it would
be reasonable to consider it when the family history
reveals two or more first degree relatives with PC,
especially if the individual is a smoker and/or has
chronic pancreatitis.
Similarly there are no established standards for
what constitutes an acceptable screening protocol [2].
The possibilities include the use of tumour markers,
but current markers (e.g. Ca 19-9 and CEA) do not
have adequate sensitivity for screening. Imaging
technologies, including computed tomography (CT),
magnetic resonance imaging (MRI) and ultrasound
(US) scanning do not have adequate resolution to
detect PC precursor lesions. Endoscopic retrograde
pancreatography (ERP) is probably too invasive as a
primary screening tool. The most promising approach
is endoscopic ultrasonography (EUS), but it is highly
operator-dependent and not widely available outside
major centres. EUS can detect quite subtle changes,
abnormal changes associated with pancreatic intrae-
pithelial neoplasia, including parenchymal heteroge-
neity, echogenic foci and hypoechoic nodules.
There are a number of requirements for screening
which EUS appears to fulfill. It is able to detect PC
earlier than diagnosis by symptoms, and the risks of
EUS are known and probably acceptable. Cost benefit
information and proof that EUS screening improves
outcome in high-risk individuals are not available.
The first screening study combined both EUS and
ERCP in testing 35 members of 13 FPC families at
the University of Washington Medical Centre, Seattle
[17]. There were 12 (34%) individuals with abnorm-
alities, all of whom had a pancreatectomy. An update
on this series shows that a total of 15 patients have had
a pancreatectomy (12 total, 3 partial) [8]. Histology
revealed no invasive cancer, but they were all found to
have dysplasia PanIN II (n/5) and PanIN III (n/
10). This group went on to perform a decision
analysis on EUS screening [18]. It was concluded
that EUS-based screening of FPC kindreds is cost-
effective, although the benefit appears to be limited to
populations with a pre-test probability of pancreatic
dysplasia of 16% or greater and in individuals under
70 years of age. The degree of dysplasia was not
specified.
The second important screening study used EUS
alone as the primary screening tool in 38 high-risk
asymptomatic individuals at the Johns Hopkins Med-
ical Institution, Baltimore and the Mayo Clinic,
Rochester [19]. Abnormalities found on EUS were
then screened with EUS-guided fine-needle aspiration
for cytology, ERCP and CT scanning. There were six
pancreatic masses identified (one invasive ductal
adenocarcinoma, one benign intraductal papillary
mucinous neoplasm (IPMN), two serous cystadeno-
mas and two non-neoplastic masses) and seven other
incidental symptomatic gastrointestinal findings. Of
the six masses, only two were clinically significant
pancreatic neoplasia, giving a clinically significant
yield of 5% (2/38) or 1:20.
These studies demonstrate that screening with EUS
is feasible and can detect significant asymptomatic
pancreatic neoplasms; however, a number of ques-
tions remain to be answered. At what age and
comorbidity should screening not be performed?
Does PanIN II warrant a pancreatectomy? What are
the significance and natural history of EUS-detected
chronic pancreatitis-like abnormalities?
The following are acceptable guidelines for screen-
ing high-risk individuals [20]:
. Primary screening should be undertaken using
EUS after genetic counselling.
. Screening should be done in an expert centre as
success is operator dependent.
. Screening should not be done unless pancrea-
tectomy would be considered for dysplasia/early
cancer.
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. Screening is less useful if there is concurrent
chronic pancreatitis or significant alcohol history.
. Screening should be initiated at 50 or 10 years
before the earliest age of onset of PC in a family
member.
. Annual surveillance is reasonable.
Less invasive and more sensitive approaches to
screening are required. The potential exists in the
future for the use of genomic or proteomic biomarker
analyses of pancreatic juice, serum, urine or stool
samples.
Treatment
When an abnormality is found on screening there is a
choice between ongoing surveillance, until a mass
develops, or obtaining a tissue diagnosis. The Wa-
shington group obtain the latter by a laparoscopic
distal pancreatectomy [21]. The role of prophylactic
pancreatectomy cannot be recommended in asympto-
matic high-risk individuals without evidence of dys-
plastic pancreatic lesions, given the significant
morbidity of the procedure and the unknown pene-
trance in the different settings of inherited PC [3].
The management of patients with a PanIN II lesion is
uncertain because the natural history is unknown.
Patients with a PanIN III lesion and no mass can be
offered continuing surveillance or a total pancreatect-
omy, because of the multifocal and widespread nature
of precursor lesions [8]. Patients must be informed of
the risks and consequences of total pancreatectomy.
Preoperative education by a diabetologist is advisable.
Prevention
The most important preventative measure is to stop
smoking. Assistance for this should be offered.
Chemoprevention is a promising concept in this field,
but not more than that. When an effective agent is
available, gene testing will assume a critical role in the
management of high-risk individuals.
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